Is this you? Create Your Porfile
Avatar

A. Navarro Mendivil

Hebron University

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where A. Navarro Mendivil is active.

Explore More

Publication

Featured researches published by A. Navarro Mendivil.

Annals of Oncology | 2016

A phase Ib study of lumretuzumab, a glycoengineered monoclonal antibody targeting HER3, in combination with carboplatin and paclitaxel as 1st-line treatment in patients with squamous non-small cell lung cancer

J.M. Cejalvo; T. Fleitas; E. Felip; A. Navarro Mendivil; Maria Martinez-Garcia; Álvaro Taus; N. Leighl; Ulrik Niels Lassen; M. Mau Soerensen; Celine Adessi; Francesca Michielin; Wolfgang Jacob; Ian James; Maurizio Ceppi; Martin Weisser; A. Cervantes

Annals of Oncology | 2014

1556O_PRANALYSIS OF EXPRESSION OF PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) IN MALIGNANT PLEURAL MESOTHELIOMA (MPM)

S. Cedres; S. Ponce Aix; Jon Zugazagoitia; A.B. Anguita; I. Sansano; A. Navarro Mendivil; A. Martinez; Pablo Martínez; P. Fidalgo; E. Felip

Annals of Oncology | 2018

1056PDPhase I experience with rogaratinib in patients with head and neck cancer selected based on FGFR mRNA overexpression

M. Joerger; S Takahashi; C.M. Sayehli; S Slosarczyk; A. Navarro Mendivil; P. Cassier; Hendrik Nogai; C Zhang; F Sei; Sebastian Bender; Peter Ellinghaus; M Tahara

Annals of Oncology | 2018

1672PMaintenance treatment with the TLR9 agonist lefitolimod in extensive-stage small-cell lung cancer (ES-SCLC): Final results from the randomized phase II IMPULSE study

Michael Thomas; S. Ponce Aix; A. Navarro Mendivil; J. Riera Knorrenschild; M. Schmidt; E Wiegert; K Kapp; C Mauri; M. Domine Gomez; J. Kollmeier; Parvis Sadjadian; K-P Fröhling; Rudolf M. Huber; M. Wolf

Annals of Oncology | 2018

1806PDMultiple primary cancers (MPC) in a series of lung cancer (LC) patient: Incidence and outcome

S Cedres Perez; M Sanso; A Hernando-Calvo; A Callejo; N. Pardo Aranda; A. Navarro Mendivil; Alex Martinez; J Remon; Josep M Miquel; G Rodriguez; V Monton; Guillermo Villacampa; R Dienstmann; Ana Vivancos; E. Felip Font

Annals of Oncology | 2018

110PImmune prognostic index (IPI) and hyper-progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in phase I trials (Ph1T): Can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios?

I Matos Garcia; Analia Azaro; Cristina Viaplana; Cinta Hierro; Juan Martin-Liberal; Irene Brana; Itziar Gardeazabal; P Gomila; M Vieito Villar; M Ochoa De Olza Amat; E Elez Fernandez; Mafalda Oliveira; Helena Verdaguer; A. Navarro Mendivil; Maria Alsina; Josep Tabernero; T Macarulla Mercadé; R Dienstmann; Elena Garralda

Annals of Oncology | 2017

1527OTop-line data from the randomized phase 2 IMPULSE study in small-cell lung cancer (SCLC): Immunotherapeutic maintenance treatment with lefitolimod

Mike Thomas; S. Ponce-Aix; A. Navarro Mendivil; J. Riera Knorrenschild; M. Schmidt; M. Krikow; E Wiegert; M. Domine Gomez; J. Kollmeier; Parvis Sadjadian; K-P Fröhling; Rudolf M. Huber; M. Wolf

Annals of Oncology | 2016

Analysis of outcomes and brain metastases (BM) of molecular selected non-small cell lung cancer (NSCLC) patients included in clinical trials

S. Cedres; N. Pardo Aranda; A. Martinez de Castro; A. Navarro Mendivil; A. Martinez Marti; Carolina Ortiz; Fabricio Racca; Marta Vilaro; LLuisa Carbonell; Adelaida Piera; I. de la fuente; E. Felip

Annals of Oncology | 2016

developmental therapeuticsPhase I study of the pan-fibroblast growth factor receptor (FGFR) inhibitor BAY 1163877 with expansion cohorts for subjects based on tumor FGFR mRNA expression levels

M. Joerger; R. Soo; B.C. Cho; A. Navarro Mendivil; C.M. Sayehli; H. Richly; D. Tai; D.-W. Kim; J. Wolf; P. Cassier; Peter Ellinghaus; S. Hildebrandt; S. Behre; C. Helmbrecht; S. Kerpen; D. Zielinski; S. Ince; P. Rajagopalan; M. Ocker; M. Schuler

Annals of Oncology | 2016

KRAS mutations(m) in lung adenocarcinoma (AC) patients(p) receiving standard chemotherapy (ch) and immune checkpoint inhibitors (i-CI): Impact of KRAS clonality and coexisting TP53m

N. Pardo Aranda; Fiorella Ruiz; A. Martinez Marti; S. Cedres; A. Navarro Mendivil; I. de la fuente; A. Martinez de Castro; Ana Vivancos; Rodrigo Dienstmann; E. Felip

Explore More

Collaboration

Dive into the A. Navarro Mendivil's collaboration.

Top Co-Authors
Avatar

J. Riera Knorrenschild

University of Marburg

View shared research outputs
Top Co-Authors
Avatar

Mike Thomas

University of Southampton

View shared research outputs
Top Co-Authors
Avatar

Manuel Domine

Autonomous University of Madrid

View shared research outputs
Top Co-Authors
Avatar

M. Joerger

Kantonsspital St. Gallen

View shared research outputs
Top Co-Authors
Avatar

Parvis Sadjadian

Ruhr University Bochum

View shared research outputs
Top Co-Authors
Avatar

Peter Ellinghaus

Bayer

View shared research outputs
Top Co-Authors
Avatar

A. Cervantes

University of Valencia

View shared research outputs
Top Co-Authors
Avatar

Itziar Gardeazabal

University of Navarra

View shared research outputs
Top Co-Authors
Avatar

Maria Martinez-Garcia

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors
Avatar

Rodrigo Dienstmann

Autonomous University of Barcelona

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge